La Jolla Pharmaceutical Company (LJPC) Shares Bought by Teachers Advisors LLC
Teachers Advisors LLC boosted its stake in La Jolla Pharmaceutical Company (NASDAQ:LJPC) by 12.4% during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 25,390 shares of the biopharmaceutical company’s stock after buying an additional 2,791 shares during the period. Teachers Advisors LLC owned 0.14% of La Jolla Pharmaceutical Company worth $445,000 as of its most recent SEC filing.
Separately, Perceptive Advisors LLC purchased a new position in shares of La Jolla Pharmaceutical Company during the fourth quarter worth about $23,127,000.
La Jolla Pharmaceutical Company (LJPC) traded up 1.48% on Friday, hitting $32.88. 152,196 shares of the stock were exchanged. The company’s 50-day moving average is $29.29 and its 200-day moving average is $26.14. The company’s market cap is $727.40 million. La Jolla Pharmaceutical Company has a 52 week low of $14.63 and a 52 week high of $39.28.
La Jolla Pharmaceutical Company (NASDAQ:LJPC) last announced its earnings results on Thursday, April 27th. The biopharmaceutical company reported ($1.26) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($1.34) by $0.08. La Jolla Pharmaceutical Company had a negative return on equity of 89.72% and a negative net margin of 12,692.37%. On average, analysts predict that La Jolla Pharmaceutical Company will post ($4.89) earnings per share for the current year.
TRADEMARK VIOLATION NOTICE: “La Jolla Pharmaceutical Company (LJPC) Shares Bought by Teachers Advisors LLC” was published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece on another domain, it was copied illegally and republished in violation of US and international trademark and copyright legislation. The legal version of this piece can be read at https://www.thecerbatgem.com/2017/07/16/teachers-advisors-llc-increases-stake-in-la-jolla-pharmaceutical-company-ljpc-updated-updated-updated.html.
LJPC has been the subject of a number of recent research reports. Jefferies Group LLC reaffirmed a “buy” rating and issued a $40.00 target price on shares of La Jolla Pharmaceutical Company in a report on Wednesday, March 29th. SunTrust Banks, Inc. reissued a “buy” rating and issued a $57.00 price objective on shares of La Jolla Pharmaceutical Company in a research note on Saturday, April 22nd. Zacks Investment Research raised shares of La Jolla Pharmaceutical Company from a “sell” rating to a “hold” rating in a research note on Wednesday, April 26th. Cowen and Company reiterated a “buy” rating and issued a $55.00 price objective on shares of La Jolla Pharmaceutical Company in a research report on Friday, April 28th. Finally, Noble Financial reiterated a “buy” rating on shares of La Jolla Pharmaceutical Company in a research report on Sunday, April 30th. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the company. The company currently has a consensus rating of “Buy” and an average price target of $43.17.
About La Jolla Pharmaceutical Company
La Jolla Pharmaceutical Company is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapies to improve outcomes in patients suffering from life-threatening diseases. LJPC-501 is its formulation of angiotensin II for the potential treatment of catecholamine-resistant hypotension (CRH).
Receive News & Stock Ratings for La Jolla Pharmaceutical Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for La Jolla Pharmaceutical Company and related stocks with our FREE daily email newsletter.